A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Summary

Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.

Timeline

Start

2022-01-04

Primary completion

2023-03-06

Completion

2024-07-22

Publications

• Tian Z, Li X, Li L, Zhang Q, Wang J, Shi Y, Peng D, Ma W, Yang P, Cheng X, Jin W, Wang F, Xie Y, Pan B, Florea V, Zhang S. Long-Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER-CN Study. J Am Heart Assoc. 2026 Jun 2;15(11):e046251. doi: 10.1161/JAHA.125.046251. Epub 2026 May 25.
• Tian Z, Li X, Li L, Zhang Q, Wang J, Shi Y, Peng D, Ma W, Yang P, Cheng X, Jin W, Wang F, Memaj A, Xie Y, Pan B, Florea V, Zheng J, Zhong Y, Zhang S. Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study. Cardiol Ther. 2026 Jun;15(2):185-200. doi: 10.1007/s40119-026-00449-5. Epub 2026 May 21.
• Tian Z, Li L, Li X, Zhang Q, Peng D, Ma W, Yang P, Wang F, Cheng X, Fu Y, Sun J, Wang J, Zhang S. Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Asia. 2025 Aug;5(8):1064-1074. doi: 10.1016/j.jacasi.2025.05.015. Epub 2025 Jul 8.
• Tian Z, Li X, Li L, Zhang Q, Wang J, Shi Y, Peng D, Yang P, Ma W, Wang F, Jin W, Cheng X, Chen YM, Zhong Y, Barrett YC, Zheng J, Zhang S. Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study. Cardiol Ther. 2025 Jun;14(2):267-282. doi: 10.1007/s40119-025-00409-5. Epub 2025 Apr 29.
• Tian Z, Li L, Li X, Wang J, Zhang Q, Li Z, Peng D, Yang P, Ma W, Wang F, Jin W, Cheng X, Sun J, Fu Y, Lyu C, Zhang S. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial. JAMA Cardiol. 2023 Oct 1;8(10):957-965. doi: 10.1001/jamacardio.2023.3030.
• Tian Z, Wang F, Jin W, Zhang Q, Zhou J, Yang P, Wang G, Hsu P, Sun J, Zhang S, Han Y. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy. BMJ Open. 2023 Jun 19;13(6):e071473. doi: 10.1136/bmjopen-2022-071473.

Drugs

Indications